Amylgen’s Articles & Posters -Amylgen

2018/02/19

Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer’s disease suggested

Amylgen’s murine model demonstrates the efficacy of RegenLife ’s device application for the treatment of Alzheimer’s disease Regenlife is opening doors to new treatment options for Alzheimer’s […]

2018/02/19

Amylgen’s murine model demonstrates the efficacy of RegenLife ’s device application for the treatment of Alzheimer’s disease

Regenlife is opening doors to new treatment options for Alzheimer’s disease. Read the original article here.

2015/01/20

Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer’s disease model

Authors: Lahmy V1, Long R2, Morin D2, Villard V3, Maurice T1 1Inserm U 710, University of Montpellier 2 Montpellier, France ; Amylgen, Montferrier-sur-Lez France. 2Inserm […]

2015/01/09

The Effects of Sigma-1 Receptor Selective Ligands on Muscarinic Receptor Antagonist Induced Cognitive Deficits in Mice

Authors: Malik M1, Rangel-Barajas C, Sumien N, Su C, Singh M, Chen Z, Huang RQ, Meunier J, Maurice T, Mach RH, Luedtke RR. 1University of North […]